StemCell Therapy

A small clinical trial conducted by Memorial Sloan Kettering Cancer Center found that every single rectal cancer patient who received an experimental immunotherapy treatment had their cancer go into remission.

One participant, Sascha Roth, was preparing to travel to Manhattan for weeks of radiation therapy when the results came in,Memorial Sloan Ketteringsaid. That's when doctors gave her the good news: She was now cancer-free.

"I told my family," Roth told The New York Times. "They didn't believe me."

These same remarkable results would be seen in14 patientsto date. The study was published Sundayin the New England Journal of Medicine. All of the patients had rectal cancer in a locally advanced stage, with a rare mutation calledmismatch repair deficiency(MMRd).

They were given six months of treatment with an immunotherapy drug called dostarlimab, from the pharmaceutical company GlaxoSmithKline, which helped fund the research. The cancer vanished in every single one of them undetectable by physical exam, endoscopy, PET scans or MRI scans, the researchers said.

The drug costs about $11,000 per dose, The Times reports. It was administered to each patient every three weeks for six months, and it works by exposing cancer cells so the immune system can identify and destroy them.

"This new treatment is a type of immunotherapy, a treatment that blocks the 'don't eat me' signal on cancer cells enabling the immune system to eliminate them," CBS News medical contributor Dr. David Agus explains.

"The treatment targets a subtype of rectal cancer that has the DNA repair system not working. When this system isn't working there are more errors in proteins and the immune system recognizes these and kills the cancer cells."

After six months or more of follow-up, the patients continued to show no signs of cancer without the need for the standard treatments of surgery, radiation and chemotherapy and the cancer has not returned in any of the patients, who have now been cancer-free for a range of six to 25 months after the trial ended.

"Amazing to have every patient in a clinical trial respond to a drug, almost unheard of," Agus said, adding that it "speaks to the role of personalized medicine that is identifying a subtype of cancer for a particular treatment, rather than treating all cancers the same."

Another surprise from the study was that none of the patients suffered serious side effects.

"Surgery and radiation have permanent effects on fertility, sexual health, bowel and bladder function," Dr. Andrea Cercek, a medical oncologist and principal investigator in the study, said in an MSKnews release. "The implications for quality of life are substantial, especially in those where standard treatment would impact childbearing potential. As the incidence of rectal cancer is rising in young adults, this approach can have a major impact."

"It's incredibly rewarding," Cercek said, "to get these happy tears and happy emails from the patients in this study who finish treatment and realize, 'Oh my God, I get to keep all my normal body functions that I feared I might lose to radiation or surgery.'"

Researchers agree the trial needs to now be replicated in a much bigger study, and noted that the small study focused only on patients who had a rare genetic signature in their tumors. But they say that seeing complete remission in 100% of patients tested is a very promising early signal.

Dr. Hanna K. Sanoff of the University of North Carolina's Lineberger Comprehensive Cancer Center, who was not involved in the study, said it is not yet clear if the patients are cured.

"Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure," Dr. Sanoff wrote in an editorial accompanying the paper.

But she noted, "These results are cause for great optimism."

The trial is expected to include about 30 patients, which will give a fuller picture of how safe and effective dostarlimab is in this group.

"While longer follow-up is needed to assess response duration, this is practice-changing for patients with MMRd locally advanced rectal cancer," said study co-leader Dr. Luis Diaz Jr., head of the division of solid tumor oncology at MSK.

Natacha Larnaud is a social TV producer for CBS News.

The rest is here:
Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News

ReportLinker

The growth in the Middle East molecular diagnostics market is expected to be driven by factors such as the increasing prevalence of infectious diseases and various types of cancer in the Middle East, rising awareness of personalized medicine and its acceptance, coupled with the significant number of funding for executing R&D in Middle East region.

New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Middle East Molecular Diagnostics Market - Country Analysis: Focus on Product, Testing Location, Technology, Application, End User, and Country Data - Analysis and Forecast, 2021-2031" - https://www.reportlinker.com/p06284299/?utm_source=GNW

Market Lifecycle Stage

Diagnostics is a well-developed market with an integral part of medical decision-making -aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare.Molecular diagnostics has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics.

Most of the players in the Middle East molecular diagnostics market offer products encompassing the kits and reagents, instruments, and software categories.

Increasing investments in the R&D for molecular diagnostics is one of the major opportunities in the Middle East molecular diagnostics market. Several diagnostics and pharmaceutical companies are working collaboratively to develop next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), microarray, nucleic acid amplification-, or mass spectrometry-based molecular diagnostics for the applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.

Impact

Several techniques are employed in modern molecular diagnostics to detect and quantify specific DNA or RNA sequences, as well as proteins. Some of these additional technologies are described briefly below: Immunohistochemistry (IHC): IHC is the utilization of monoclonal and polyclonal antibodies for the detection of specific antigens in tissue sections. In Situ Hybridization (ISH or FISH): This is a technique that unwinds DNA or RNA in the sample and employs a labeled DNA or RNA strand (probe), which hybridizes with the complementary sequence on an unwound strand (target). Polymerase Chain Reaction (PCR): Polymerase chain reaction (PCR) allows researchers to amplify a small amount of DNA to quantities that can be used for analysis. PCR has ushered in a golden era in molecular diagnostics. Sequencing (CE, NGS): The sequencing allows the mapping of the entire sequence of the nucleotides that comprise a strand of DNA. As of 2020, sequencing can be achieved through capillary electrophoresis (CE) or through multiple next-generation sequencing (NGS) methods.

Impact of COVID-19

The current Middle East molecular diagnostics market comprises software, instruments, and consumables.It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, that have led to reduced usage of instruments, consumables, and software related to research.

Overall, the impact of COVID-19 on the Middle East molecular diagnostics market size has been low-moderate.Some of the market players have reported a slight decline in sales.

However, financials are already on their way to recovery.The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain.

The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most of the key markets across the Middle East. However, the pandemic has played a key role in enhancing the growth prospects of molecular diagnostics and is expected to indirectly aid in improving the market growth outlook.

Market Segmentation

Segmentation 1: by Product Systems Kits and Consumables Software and Other Products

The Middle East molecular diagnostics market in the products segment is expected to be dominated by the kits and consumables segment. This is due to an increasing number of molecular diagnostics kit providers offering kits and services to their end users.

Segmentation 2: by Testing Location Laboratory Testing Point-of-Care Testing

The Middle East molecular diagnostics market is dominated by the laboratory testing segment owing to an increasing number of molecular diagnostic laboratories in the Middle East region involved in undertaking various routine testing for different chronic and acute diseases.

Segmentation 3: by Technology Polymerase Chain Reaction (PCR) Next-Generation Sequencing (NGS) Isothermal Nucleic Acid Amplification Technology (INAAT) Microarray In-Situ Hybridization (ISH) Immunohistochemistry (IHC) Other Technologies

The polymerase chain reaction segment dominates the Middle East molecular diagnostics market due to the increasing number of PCR testing being carried out in the Middle East laboratories for diagnosis.

Segmentation 4: by Application Core Molecular Diagnostics Reproductive Genetics Companion Diagnostics Liquid Biopsy Others

The core molecular diagnostic segment dominates the Middle East molecular diagnostics market due to the rising number of molecular testing in laboratories to cure diseases. Core molecular diagnostics applications include a large number of inclusive applications that cater to the major portion of the Middle East molecular diagnostics market.

Segmentation 5: by End User Hospitals Diagnostic Centres Outpatient Clinics/General Practitioners Research Laboratories Others

The hospitals segment dominates the Middle East molecular diagnostics market as hospitals, particularly in Middle East countries have incorporated extensive molecular diagnostics portfolios to provide superior care to patients suffering from diseases.

Segmentation 6: by Countryo Kingdom of Saudi Arabia (K.S.A.)o Israelo United Arab Emirates (U.A.E.)o Egypto Irano Qataro Other Countries

K.S.A. generated the highest revenue of $132.5 million in 2020. The Kingdom of Saudi Arabia (K.S.A.) has a huge population base suffering from various diseases and rising healthcare costs in the region. Medical research in the Kingdom of Saudi Arabia (K.S.A.) has gained momentum since 2013 and is heavily being invested in by the local government. The government is extensively supporting research organizations with projects aimed at improving the understanding and treatment of diseases affecting the Saudi population.

Recent Developments in Middle East Molecular Diagnostics Market

In January 2022, Abbott showcased its life-changing diagnostic tools and medical devices product portfolio for point-of-care testing (POCT) that helped COVID-19, diabetes, and cardiovascular disease patients at MEDLAB Middle East. In June 2021, biomeruix launched EPISEQ SARS-COV-2 to identify SARS-CoV-2 variants using samples from COVID-19 positive patients. In 2021, the BD. company declared the approval of the BD Veritor At-Home COVID-19 Test for the detection of SARS-CoV-2 with definitive digital results at home. In 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a Middle East leader in multiplex molecular diagnostics, for the commercialization and clinical development of molecular diagnostic products.

Demand Drivers and Limitations

Following are the demand drivers for the Middle East Molecular Diagnostics Market: Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East Increase in Awareness and Acceptance of Personalized Medicines in the Middle East Significant External Funding for Executing Research and Development Exercises

The market is expected to face some limitations too due to the following challenges: Uncertain Reimbursement Scenario Lack of High-Complexity Testing Centers in the Middle East

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Major manufacturers of the Middle East molecular diagnostic market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly molecular diagnostics.PCR has gradually evolved from gel analysis to real-time PCR to, more recently, digital PCR.

In digital PCR, amplification of individual targets is done in picolitre to nanoliter volumes, and instead of standard curves or internal controls, statistics are employed to calculate target concentrations.Genome-wide studies have gone beyond unknown expeditions, and disease association studies that use the expression, single nucleotide polymorphism, and copy number microarrays have identified useful markers that have been reduced to practical molecular tests.

Big data needs have resulted in new bioinformatics tools that continue to evolve rapidly.

Competitive Strategy: Key players in the Middle East molecular diagnostics market analyzed and profiled in the study have been involved as the Middle East molecular diagnostics-based product manufacturers that provide software and molecular diagnostic services.Moreover, a detailed competitive benchmarking of the players operating in the Middle East molecular diagnostics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are: Abbott Agilent Technologies, Inc. bioMrieux SA BD Babirus Medical Equipment LLC Bio-Rad Laboratories, Inc. Danaher F. Hoffmann-La Roche Ltd. Guardant Health Illumina, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc.

Countries Covered K.S.A. Israel U.A.E. Egypt Iran Qatar Rest-of-the-Middle EastRead the full report: https://www.reportlinker.com/p06284299/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Excerpt from:
The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the...

An estimated 90% of clinical trials centered on cancers fail, sending those potential oncological treatments either to the drawing board or the scrap heap. Each unsuccessful trial means billions lost in R&D investment and, potentially, countless lives.

During this years BIO International Convention (taking place June 13-16 in San Diego), a group of industry professionals will share with attendees reasons why it doesnt have to be that way. Matthew Clark, board member and advisor with CerFlux, is one of the panelists speaking during Cancer Trials Dont Have to Fail 90% of the Time. Seriously, scheduled at 11 am PDT on Wednesday, June 15; Outsourcing-Pharma recently connected with Clark to learn about the session, and how cancer-centered trials might be able to improve their prognosis.

OSP: Could you please share your thoughts about the high failure rate of cancer trials, and how that proportion has changed over the years?

MC: One of the clearest presentations of this data from 2004 through 2015 is a study by Wong and colleagues in 2019 that indicated a 3.4% probability of success for oncology development efforts. Their research also revealed that over the last twenty years there has been little change in the probability of success of clinical trials as they vacillated around 5%.

The most recent results published by BIO last year showed a roughly 5.4% likelihood of success from preclinical to FDA approval for cancer treatments. This reveals that in terms of outcomes there is little improvement over the last 20 years.

OSP: In a nutshell, what are some of the reasons (big and small) for that high rate?

MC: There are numerous reasons for this high failure rate. Ill highlight only a few that require our attention. Perhaps the biggest reason is that cancer involves many variables involving heterogeneous populations and disease presentations. This conclusion is further evident from the consistently low failure rate of clinical trials prior to approval (90-98% failure) over more than a decade and the low probability of successful therapy (<25%) from FDA-approved therapeutics. This suggests that we consistently choose a target for therapy that cannot be demonstrated via traditional clinical trials.

Another reason related to multivariate factors in clinical trials for cancer pharmaceutical developments includes challenges with inclusion criteria for clinical trial participants. Simply put, the clear suggestion is that we are not testing the right products, focused on the right factors or outcome variables for clinical benefit, in the right populations or models, at the right time prior to going to clinical trial. We have to remember that clinical trials should be demonstrations of clinical utility rather than exploratory in nature or purpose.

OSP: What kinds of solutions might pharma companies and their research partners have tackled in the past to try and bring that number down?

MC: Biomarkers are perhaps the focus of the greatest push over the last nearly 20 years in the pharmaceutical industry. Most pointedly, there is a focus on omics to identify appropriate biomarkers. These approaches include proteomics, genomics, and metabolomics, to name a few, and are developing towards multi-omics.

Since the early 2000s, the argument has been that they can make a big difference, particularly when combined with existing techniques. The method is effective for exploratory research but has not produced the consistent results needed for the traditional groups-based designs generally used in clinical trials.

Similarly, cell-line-derived xenografts, patient-derived xenografts, and genetically modified animal models have generated lots of excitement because they attempt to mimic complex microenvironments or biological processes leading to or promoting cancer. These methods are expensive, time-consuming, and ultimately serve as a model that may not generalize back to the human disease state.

Unfortunately, the success of all of these approaches is less than clear as indicated by the consistently low probability of success or likelihood of approval at around 5% for more than 20 years. These efforts may have potential in the preclinical and exploratory arena, but to date, they have had little value in clinically relevant, therapeutic pharmaceutical development in the aggregate.

OSP: How can personalized medicine help elevate oncological drug development?

MC: A primary goal of personalized medicine is to tackle the heterogeneity of cancer directly. At the core, cancer is personalized, so the treatment of cancer must likewise be personalized.

However, the strategies for clinical success generally require group-based designs. This means the goal is to use individual responses to both the disease and possible therapeutics to identify the factors or biological processes at the right time allowing for better targets for therapeutic development that are not only effective but also have fewer side effects.

Through personalized medicine, we can take a more refined and nuanced approach to the treatment of different cancers that manifest in categorical and specific ways that treat the factors evident for a subgroup of those with the disease. Focused development will lead to more focused and more effective drug indications.

Done effectively, we believe that personalized medicine can further reduce the costs and time of drug development by elucidating what factors matter when in the progression of the disease. Therefore, personalized medicine can reduce the noise that historically plagued the development of drugs for cancer ultimately upending the vast majority of clinical trials.

We believe that with personalized medicine we can address the variability inherent in cancer by better identifying and aligning the idiosyncratic and temporal aspects of cancer with the concomitant treatments that are required; essentially, synchronizing the variability in cancer with the array of therapeutic formulations like two overlapping sine curves instead of interference from being out of phase.

Another outcome of personalized medicine is that it can help reduce hesitancy to participate in clinical trials through better target selection concurrently with off-target identification. It also will improve inclusion criteria, endpoint selection for trials, clinical trial planning, and decrease the cycle time for trials to enroll and complete. Each of these is a challenge to the development of cancer therapeutics that personalized medicine can improve.

OSP: How can companies like yours help drug development pros harness PM to put their cancer treatment candidates on a more favorable path?

MC: The hallmark of the CerFlux platform is providing a preview of clinical response well in advance of clinical development through ex vivo screening and analytics of drugs, or combinations of drugs, directly against actual tumor biopsy. Such previews could vastly improve productivity and returns by redirecting investment in more productive assets early and also improve patient outcomes.

Screening directly against tumor biopsies allows us to evaluate and better appreciate the heterogeneity and complexity of cancer in relevant ways that should be predictive of clinical outcomes. For instance, directly analyzing patient tumor biopsy avoids distortion of tissue composition and microarchitecture resulting from dissociation or expansion. Further, since core biopsies are standard of care for many solid tumors, such evaluation would add minimal burden on patients and clinical care teams.

Finally, assessment of standard of care biopsies would also mitigate racial and ethnic biases. This would allow pharmaceutical companies to better target their limited resources on drugs that are likely to have a higher probability of success on a broader population while further reducing the probability of negative side effects. Of course, our approach will not be a panacea, but we believe that it will be a notable improvement over the current approach that is clearly not working. Over time, iterative and incremental improvements through our process will help people find ways to live productive lives with cancer.

OSP: Do you have anything to add?

MC: Thank you for the opportunity to share our perspective and how we are trying to motivate change in this important area. The more we transparently challenge ourselves to be better, the greater the opportunity to partner for solutions that make a difference for thoseliving with cancer.

The BIO International Convention is scheduled June 13-16 at the San Diego Convention Center. Visit the show website for more information or to register.

More here:
Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com

When Alzheimers disease was believed to be caused solely by the accumulation of amyloid protein in the brain, pinning all hopes on an amyloid-targeting drug like Aduhelm the first drug approved to treat Alzheimers in 17 years made sense. But newer knowledge that ties Alzheimers to the biology of aging indicates the disease is caused by a combination of age-related changes in the brain that affect different people in different ways.

That means neither Aduhelm nor any anti-amyloid drug on its own will be a cure for the estimated 6.2 million Americans living with Alzheimers. The next phase of research must focus on promising drugs that target a host of underlying pathologies that contribute to Alzheimers.

Today more than ever, research is embracing this new understanding, taking a more diversified multiple shots on goal approach to new drug targets. More than three in four treatments currently in clinical development work against non-amyloid targets. These include drugs to reduce inflammation in the brain, improve blood flow, clear misfolded proteins, improve how the brain metabolizes energy, and more.

advertisement

To complement these pathways, new biomarkers are needed that will give physicians like me the tools needed to zero in on the causes of each patients Alzheimers and tailor combinations to provide precision personalized medicine.

Alzheimers research is notoriously challenging and expensive, outstripping cost estimates for research in most other therapeutic areas. The brain is incredibly complex, and while Alzheimers is the most common cause of dementia, it is not the only one. But Im more optimistic than ever about whats coming down the pipeline because Alzheimers research has moved into a modern era, not only in the breadth of its targets but in its ability to implement more rigorous clinical trials that track and determine the relationship between biomarker and clinical outcomes.

advertisement

If Aduhelm and other anti-amyloid antibodies that follow it are, at best, just one incremental piece of the puzzle, how do the blanks get filled in? For a start, it is time for everyone in the Alzheimers ecosphere to look toward a broader and more diverse approach to curing this devastating disease and speed the development of new, effective therapies to treat and prevent Alzheimers disease and related dementias.

A critical driver of better and faster clinical trials are biomarkers objectively measurable biological and behavioral characteristics that correlate with Alzheimers disease that are essential for improving trial design and quickly advancing the current pipeline of novel targets.

Biomarkers are already being used to great effect in early-stage trials, quickly telling researchers whether an experimental drug is engaging with its intended target in the brain. They are also playing a larger role in later-stage trials, providing better and quicker ways to screen and enroll patients whose Alzheimers disease profile includes the characteristic the experimental drug is meant to work on, and then by providing an easy means for tracking the effects of treatment. Biomarker data from brain amyloid PET scans, for example, provided the primary data for Aduhelms Food and Drug Administration accelerated approval.

Biomarkers are also making their way into clinical practice. Physicians can now use tests of blood and cerebrospinal fluid to measure brain amyloid levels in people experiencing early signs of mild cognitive impairment or dementia. The day will soon come when a simple blood sample, retina scan, or even a smartphone app will be able to identify underlying causes of Alzheimers during a doctor visit, allowing for treatment to be matched to a patients unique pathology.

As more drugs are developed against a wide range of targets, biomarkers must play a bigger role than ever in clinical trials. Researchers worldwide are working toward validating additional blood and other non-invasive tests that can measure brain levels of everything from tau and other toxic proteins to biological indicators of neuroinflammation, synaptic malfunction, and changes in metabolism. These new biomarker tests will be essential for both clinical trials and clinical practice.

Alzheimers researchers need to work together to conduct more biomarker-powered exploratory trials to more quickly and effectively assess whether a drug has promise. By adopting best practices in designing exploratory trials, researchers and companies can be more confident in using their results to make the all-important go/no-go decisions about advancing drugs to larger, later-stage trials.

In 2019, the Alzheimers Drug Discovery Foundation (which I co-founded) and the Association for Frontotemporal Degeneration convened an advisory panel of experts to provide recommendations on ways to optimize the design and application of exploratory trials. The panels recommendations, published last year in the journal Neurology, are designed to improve trial designs and engage patients more efficiently. When it comes to clinical trials, participants are a limited resource, so it is vitally important, especially for rarer forms of dementia, that they are matched to the right trials and that these trials run as efficiently as possible so each patients involvement is valued and maximized.

Policies that support efforts to bring repurposed drugs to the market are also urgently needed. Repurposed drugs start with an advantage because some of the research, including essential information about safety in humans, has already been done. But they are hampered by the economic disadvantage of limited returns on investment.

The pressure from patient advocacy groups for the FDA to approve and for Medicare to cover Aduhelm a drug that was at best only going to have a modest incremental benefit reflects the understandable public hunger for new Alzheimers treatments. It also underscores the urgent need for better ways to get effective drugs to market for the millions living with Alzheimers.

Its encouraging to see broader consensus in the research community for the need to take fresh looks at the biology of aging. In a 2021 Alzheimers Clinical Trials report, the Alzheimers Drug Discovery Foundation analyzed the approximately 120 clinical trials underway that are tackling a variety of age-related pathways.

These efforts will open the doors to new breakthroughs and the kinds of combination therapies that have changed the lives of people with cancer, diabetes, HIV, and other diseases. At this pivotal moment, academia, industry, regulatory agencies, patient advocates, venture philanthropists, and others need to work together as a community to accelerate the move into this new era of treatment possibilities for people with Alzheimers.

Howard M. Fillit is a neuroscientist and geriatrician, the co-founder and chief science officer of the Alzheimers Drug Discovery Foundation, and a clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at the Icahn School of Medicine at Mount Sinai. He reports having consulted for various pharmaceutical companies, including Alector, LifeWorx, Eli Lilly, Otsuka Pharmaceuticals, and others.

See the rest here:
It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT

"At Illumina, customers are at the center of what we do, and we are excited to connect with them at AGBT to unveil our next-generation genomics solutions and learn more about their specific needs and requirements," said Susan Tousi, Chief Commercial Officer at Illumina. "AGBT represents a key opportunity for Illumina to continue driving innovations that accelerate personalized medicine far into the future with our many valued partners."

New, longer-read kit configurations

Expected to be released later this year, the new 600 cycle kit on NextSeq 1000/2000 will deliver longer, paired-end 2x300bp reads and expand the breadth of applications ranging from metagenomics to immune-repertoire profiling. Data will be presented demonstrating NextSeq 2000 as a powerful, new tool to enable full-length V(D)J immune repertoire sequencing at scale to further understand the human immunome.

"The upcoming launch of our new NextSeq kits is another important step towards continuing to elevate sequencing to a new industry benchmark," said Alex Aravanis, SVP and Chief Technology Officer at Illumina. "Greater gene sequencing depth and length, combined with advanced library preparation approaches, represent the next wave of technological advances in repertoire sequencing that will unlock the power of the genome to transform human health."

New data with Infinity Technology

In its June 8 session entitled "Emerging Applications and Advances in Whole Genome Sequencing," Illumina will share new data from its Infinity technology platform, demonstrating exceptional performance across difficult-to-map regions of the genome, the ability to resolve complex structural variants, and the functionality to generate phased data across the highly polymorphic human leukocyte antigen (HLA) regions to assign haplotypes. Additionally, Illumina will share data using the Infinity technology in combination with targeted enrichment. This approach allows users to target the approximately 5% of difficult-to-map genic regions in combination with a standard Illumina genome to enable unprecedented scale using a novel and cost-effective approach.

The Ashley Lab at Stanford University has been an early collaborator with Illumina and has used Infinity data to analyze patient samples to further resolve the underlying genetic variation creating another powerful tool for more informed clinical decision-making to improve patient outcomes. Euan Ashley, MD, PhD, Professor of Genomics and Precision Health, Stanford University School of Medicine, presented data generated from Infinity technology in his keynote address at AGBT on June 6.

Optimized WGS performance with NovaSeq 6000 and best-in-class informatics

Illumina's NovaSeq 6000and DRAGEN Bio-IT platform are addressing some of today's biggest global health challenges, including genetic disease diagnosis, cancer detection and treatment, and global pathogen surveillance. Illumina's recent progress in informatics is also optimizing human WGS analysis.

In a June 9 session entitled "Connecting Samples to Genomic Analysis & Interpretation," Illumina will discuss its suite of informatics solutions and highlight its game-changing applications, including DRAGEN v3.10, which provides the most accurate measurement of the genome as measured against Precision FDA benchmarks. In an updated comparison, DRAGEN outperformed all other technologies across all benchmarks and in the difficult major histocompatibility complex (MHC) region. DRAGEN v3.10 continues to deliver industry-leading accuracy across numerous population-scale studies, such as All of Us, Genome England and UK BioBank.As of March 2022, Illumina's customers have processed more than 1.8 million whole genomes through the DRAGEN tools to accelerate the data processing component of sequencing.

Convening and leading critical conversations at AGBT

Illumina will convene and drive critical conversations around genomics innovation, foster industry collaboration, and discuss advances in its genomics technologies through a number of events and discussions at AGBT, including:

"At Illumina, we are pushing genomic technologies to new frontiers to solve the world's biggest health challenges," said Aravanis. "Through our involvement in this year's AGBT, we look forward to engaging with leading genomics innovators and thinkers about the next-generation genomics solutions that are driving the future of personalized medicine and the ways we can scale these critical innovations to transform health outcomes around the world."

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; and (ii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more,visitwww.illumina.comand connect with us onTwitter,Facebook,LinkedIn,Instagram, andYouTube.

Investors:Salli Schwartz858.291.6421[emailprotected]

Media:Adi RavalUS: 202.629.8172[emailprotected]

SOURCE Illumina, Inc.

Read more here:
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire

WEST LAFAYETTE, Ind. Collaboration among Purdue University, Purdue Polytechnic Institute and Purdue University Global is leading the way to a unique partnership with the University of Puerto Rico.

A Purdue delegation of administrators, faculty and students visited Puerto Rico in March to meet with representatives and students fromfour University of Puerto Rico (UPR) campuses Bayamn, Humacao, Mayaguez and Rio Piedras as well as the Center for Marine Science at UPR-Mayaguez and the University of Puerto Rico Hospital.

The entire Purdue system is pleased to partner with the University of Puerto Rico to explore the creation and offering of new academic opportunities in an innovative fashion that serves both current and future workforce development needs, saidMelissa Burdi, Purdue University Global vice president and dean of the School of Nursing, who was part of the delegation. UPR is a highlyvalued partner, and we look forward to a dynamic and meaningful collaboration.

In a joint statement, Miguel Vlez-Rubio, chancellor for UPR-Bayamn, and Jorge F. Rovira-Alvarez, dean of academic affairs, said: The University of Puerto Rico at Bayamn is pursuing a strong collaboration partnership with Purdue University and its affiliates. We are confident that establishing agreements on diverse academic fields and services will allow both institutions to grow, and we foresee ample benefits for current students and future recruitment. It most definitively expands our academic offering and provides students with additional opportunities to develop both in professional areas and personal interests.

During the weeklong stay, Purdue students gave presentations on sustainability and climate change, biomedical innovation, emerging COVID technologies, mass migration at the U.S.-Mexico border and precision medicine and exchanged ideas with UPR students. They visited the Engine-4 coworking space, an incubator and the marine science laboratory in Mayaguez.

The focus was to forge relationships that willbenefit students and professors in disciplines such as precision medicine and health care, sustainability and climate change, and engineering. Specifically, the Purdue team initially identified three key areas to serve as a springboard for the partnership. They are:

Nursing: The Purdue University Global School of Nursing will collaborate with UPR to develop innovative education offerings and will invite nursing faculty from UPR to the Purdue West Lafayette campus for a Summer Institute to explore immersive learning virtual reality options for nursing faculty and students in Puerto Rico. Building this unique partnership affords the Purdue system and UPR the ability to co-create learning opportunities aimed at solving current and future workforce challenges within the entire health care ecosystem, where education and hands-on preparation are key, including the use of precision medicine, Burdi said.

With precision medicine, the goal is to utilize robots to disinfect critical areas in Puerto Rico hospitals while also detecting different contaminants in the hospitals air. During the COVID-19 pandemic, Purdue students worked with Luciano Castillo, theKenninger Professor of Renewable Energy and Power Systems in Mechanical Engineering at Purdue, and Richard Voyles, head of the Collaborative Robotics Lab at Purdue and director of the Robotics Accelerator, to design, build and deploy two autonomous cleaning robots to disinfect spaces.

Engineering: Purdue West Lafayette will develop a transfer program for UPR students to complete their degree in biomedical engineering and aerospace engineering. UPR-Bayamn is limited in the number of students accepted by UPR-Mayaguez into their existing programs. Additionally, this program will allow Purdue to grow its pool of diverse students in areas not offered at UPR-Bayamn, such as aerospace engineering, nuclear engineering, materials engineering and biomedical engineering. In collaboration with UPR faculty, Purdue faculty will develop a template for introductory courses. For Purdue to partner with the University of Puerto Rico to help them grow engineering programs, such as aerospace engineering and biomedical engineering, is a unique way to help grow the local workforce while increasing diversity here and promoting unique research partnerships such as Coastal Resiliency, said Mung Chiang, the John A. Edwardson Dean of the College of Engineering and Purdues vice president for strategic initiatives.

Professional development for police: UPR-Bayamn is the primary institution designated by the government to offer training opportunities for police. Purdue has identified a unique opportunity to leverage existing funding todevelop and offer high-quality professional development.

To jumpstart the partnership, UPR stakeholders have been invited to participate in the Summer Institute for Sustainability & Climate Change at Purdue West Lafayette from June 20 to Aug. 1.

Castillo is working with the Office of Naval Research (ONR) on a consortium for Historically Black Colleges and Universities and Hispanic-serving institutions to conduct this initiative with the goal of building and mentoring a diverse workforce that will solve future challenges pertaining to sustainability climate change, security and precision medicine. The target audience is K-12 students and faculty and college undergraduate and graduate students, and participants will receive a certificate of completion after taking part in the monthlong institute.

Addressing social inequality and engaging the untapped talent in our communities while solving climate change, health challenges, and security are major goals of our consortium, Castillo said. By increasing a diverse STEM workforce, we will accelerate new innovations, which will propel a strong economy in Puerto Rico, specifically in disadvantaged communities. For us to partner with the University of Puerto Rico to address problems related to coastal resiliency, renewable energy and train a strong STEM workforcewill help us build a vibrant future for the island and in the mainland.

About Purdue University

Purdue University is a top public research institution developing practical solutions to todays toughest challenges. Ranked in each of the last four years as one of the 10 Most Innovative universities in the United States by U.S. News & World Report, Purdue delivers world-changing research and out-of-this-world discovery. Committed to hands-on and online, real-world learning, Purdue offers a transformative education to all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, enabling more students than ever to graduate debt-free. See how Purdue never stops in the persistent pursuit of the next giant leap athttps://stories.purdue.edu.

About Purdue Polytechnic Institute

The Purdue Polytechnic Institute, one of the 10 academic colleges of Purdue University, provides a unique array of high-demand technology disciplines for bachelors, masters and Ph.D. degrees available on Purdues flagship campus in West Lafayette, Indiana, and at other locations throughout the state. The Polytechnics faculty and staff encourage innovation, collaboration and creativity among diverse interdisciplinary groups in the persistent pursuit of big ideas and novel approaches. Thanks to our generous alumni and engaged industry partners, Purdue Polytechnic continues the important steps of Purdues history, preparing our graduates for their successful futures.

About Purdue University Global

Purdue University Global delivers personalized online education tailored to the unique needs of adults who have work or life experience beyond the classroom, enabling them to develop essential academic and professional skills with the support and flexibility they need to achieve their career goals. It offers personalized paths for students to earn an associate, bachelors, masters or doctoral degree, based on their work experience, desired pace, military service, previous college credits and other considerations no matter where they are in their life journey. Purdue University Global is a nonprofit, public university accredited by the Higher Learning Commission. It is affiliated with Purdue Universitys flagship institution, a highly ranked public research university located in West Lafayette, Indiana. Purdue University also operates regional campuses in Fort Wayne and Northwest Indiana, as well as serving science, engineering and technology students at the Indiana University-Purdue University Indianapolis (IUPUI) campus. For more information, visit purdueglobal.edu.

Media Contact: Tom Schott, tschott@purdue.edu

Sources: Mung Chiang

Maricel Lawrence

Melissa Burdi

Luciano Castillo

Here is the original post:
Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University

NEW YORK--(BUSINESS WIRE)-- Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, and AdhereTech, a pioneer and leading provider of smart devices that connect patients to care with real-time interventions, announced their partnership to provide advanced, data-driven digital health technology solutions, focusing in oral oncolytic agents providing real-time integrated access to care for cancer patients to precision oncology drugs and leading-edge clinical trials. Both companies were recognized in the 2022 NYC Digital Health 100 which showcases the most exciting digital health companies in the New York region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005289/en/

Massive Bio and AdhereTech, two of NYC Digital Healths 100 most promising start-ups, announce a partnership to provide integrated access to precision oncology care for cancer patients. (Photo: Business Wire)

Massive Bio and AdhereTech have committed to combining their products and services to offer global, comprehensive solutions to measure, analyze and monitor precision oncology medication adherence for patients participating in clinical trials and those prescribed commercially available treatments. Both companies currently are contracted with leading pharmaceutical companies and major specialty pharmacies. Their work with payers, pharmacies and pharmaceutical companies to develop adherence programs utilizing device generated data to optimize processes and improve cost-effective measures for specialty drug and clinical trial programs that may save the industry hundreds of billions of dollars per year.

While the conversation around digital health and pharma has expanded well beyond from adherence, in oncology it provides the link between cost-effective treatments, and an opportunity to prioritize clinical trials when most appropriate mentioned Selin Kurnaz, CEO and Co-Founder of Massive Bio. Even modest improvements can lead to huge cost savings for payers and the pharmaceutical research industry, while allowing streamlined access in real time to effective on-label precision oncology treatments. It is a win-win situation for all stakeholders, from patients to specialty pharmacies, payers, and the commercial and cancer research ecosystem. AdhereTech is one of the few companies that is successfully achieving those goals, and we are excited about this collaboration.

With over 13,000 active cancer clinical trials in the US at any given time, and dozens of biomarkers and precision oncology molecules under study, Massive Bio aims to use AI and patient-centric concierge services at scale to reach cancer patients globally and accelerate the oncology research and development infrastructure. Massive Bio had recently announced the launch of its NASA-style Oncology Clinical Trial Command Center (OCTCC) to disrupt and accelerate trial enrollment, and also the launch of its 100K Cancer Clinical Trial Singularity Program aimed at matching 100,000 cancer patients in real-time to cutting-edge clinical trials using its Massive Bios AI-based technology, website and apps across iOS and Android platforms, expanding their presence as a global company with country-level success in 12 markets.

AdhereTech is a leader in medication programs, providing commercialized digital solutions to measure and manage medication adherence in a variety of settings, including academics, clinical trials, and commercially prescribed treatments. It develops and produces treatment management solutions utilizing smart devices with integrated cellular technology that, seamlessly, connects patients in real time to confirm when patients take their medication and provides two-way communications to ensure dosing regimens are followed and reports and escalates the reasons for and missed doses.

The Aidia System creates personalized patient support with specialty pharmacies and healthcare teams, enabling timely health interventions when they are necessary, and clinical trials can benefit from those key interventions, said Chris OBrien, Chief Executive Officer of AdhereTech. Upon learning of Massive Bios traction in the oncology space, and the opportunities of using our Aidia System, expansive network, and real-world data to help patients, physicians and the cancer research industry at a technology enabled scale, it made absolute sense to explore and operationalize this partnership.

Our AI-enabled clinical trial and precision oncology therapy-finding technology works at its best when paired up with real-time patient-reported insights said Arturo Loaiza-Bonilla, M.D., Co-Founder of Massive Bio. By leveraging real-time data from AdhereTechs Smart Adherence System in combination with our SYNERGY-AI cancer trial matching platform, we can identify key opportunities for clinical trial enrollment, while also optimizing medication adherence and access in both precision oncology care, and cancer research.

At AdhereTech, we strive to bring data, analytics and new technologies to market to serve patients and life science companies with better resources in the vital clinical research and treatment realms said Gregory Gallo, Chief Revenue Officer of AdhereTech. Were excited to partner with a cutting-edge solutions provider in the critical oncology therapeutic category. Collaborating, integrating technology and resources will serve to streamline patients journeys and achieve more consistent engagement, enhance care and ultimately improve outcomes and scientific advances, added Gallo.

About AdhereTech

AdhereTech is a privately held digital health company headquartered in New York, NY, and is the leading provider and pioneer of smart devices that connect patients to care via real-time interventions. AdhereTech partners with pharmaceutical manufacturers, specialty pharmacies and healthcare teams with the mission of using technology informed by insights into human behavior to improve health outcomes. Its Aidia SystemTM is a proven, integrated technology-based adherence solution that empowers patients and healthcare teams to achieve optimal medication success. For more information, please visit us at http://www.adheretech.com. You can also follow us on LinkedIn and Twitter, @AdhereTech.

About Massive Bio

Massive Bios (https://massivebio.com/) mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability. Massive Bio is an AI-driven platform connecting cancer patients and their oncologists to bio-pharmaceutical clinical trials, yielding profound improvement in access and match rates, leading to faster drug development timelines, and creating a novel oncology data ecosystem for improved protocol design and real-world insights. Massive Bio controls the patient enrollment value chain starting with patient identification, following with AI-based virtual pre-screening outside the site, and resolving last mile issues for clinical trial enrollment. While improving cancer patients lives, Massive Bio serves over two dozen pharmaceutical companies, contract research organizations (CROs) and hospital networks. In addition, Massive Bio has been awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize its Deep Learning Clinical Trial Matching System (DLCTMS), Contract No. 75N91020C00016. Selected to the "Digital Health 100" by New York City Health Business Leaders, Massive Bio provides oncology dedicated patient recruitment, site selection, real-world data services, and AI-based trial prescreening services to its enterprise customers. Massive Bio was founded in 2015, is headquartered in NYC, and is privately funded by strategic and financial investors. Follow Massive Bio on Twitter, LinkedIn, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005289/en/

The rest is here:
AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions...

Less than 2 weeks ahead of the American Diabetes Association 82nd Scientific Sessions, new data from the Diabetes Prevention Program Outcomes Study (DPPOS) provided insight into 21 years of follow-up from more than 3,200 adults with prediabetes. As with previous data releases from the program, the new data drew a lot of attention and, for many, it was because the results fly in the face of conventional wisdom: neither lifestyle interventions nor metformin reduced the cardiovascular disease risk among these patients.

With both of these approaches proven to provide benefit for reducing risk of type 2 diabetes, metformin and lifestyle interventions have established themselves as integral parts of treatment algorithms for many patients with diabetes. However, in recent years a new emphasis has been placed on not only addressing subpar glycemic control in patients with diabetes, but addressing the inherent cardiovascular and renal risk in these patients through use of newer agents, such as GLP-1 receptor agonists and SGLT2 inhibitors.

With this in mind, Endocrinology Network asked a trio of experts in diabetes and cardiometabolism what they thought of the recent data from DPPOS and whether or not it is time to shift away from metformin being a first-line therapy for patients with type 2 diabetes towards a newer agent or agents. The responses of these experts, Juan Frias, MD, of National Research Institute, W. Timothy Garvey, MD, of University of Alabama at Birmingham, and Hiddo Heerspink, PharmD, PhD, of Groningen University in the Netherlands, can be found below.

Juan Frias, MD: That is a great question. My answer would be that metformin is very inexpensive, and oftentimes free, and it is very effective in lowering the glucose. In your patients, particularly your patients with very high glucose, usually you get a greater reduction, but that's known for any medication that can do very well from a glycemic perspective with metformin.

What I would say is that we should not use metformin and delay the use of those agents, such as a GLP-1 or an SGLT2 inhibitor, in patients who are appropriate and need those agents. So, don't use metformin, to the exclusion of using the other agent. I think it could be certainly be an adjunct in a lot of patients because it does improve clearly improves glycemic control. Again, it's generic, it's inexpensive, and I would say that it's going to continue to be used. Sulfonylureas continued to be used, and I certainly think those should be phased out before metformin gets phased out.

So, we need to just make sure as the guidelines tell us, irrespective of the HbA1c and irrespective of metformin use, that patients with atherosclerotic cardiovascular disease who are at very high risk should be using GLP-1 receptor agonists or SGLT2 inhibitors with proven cardiovascular benefit. In patients with heart failure, they should be using an SGLT2 inhibitor. In patients with chronic kidney disease, an SGLT2 inhibitor and often times a combination of SGLT2 inhibitor and GLP-1 receptor agonist and I think metformin is fine to include there. What you don't want to do is be on metformin for 1-2 years and not add those other agents.

W. Timothy Garvey, MD: Well, that's a good question. But there's a subanalysis of the DPP data looking at patients that lost 10% or more of their body weight, and this subgroup did have a decrease in MACE outcomes: myocardial infarction, non fatal stroke, and this composite cardiovascular outcome measure. So, this data suggests that it boils down to achieving sufficient weight loss to achieve cardiovascular protection. We don't have these data from these weight loss medications at this point.

There is a study called SELECT that's ongoing with semaglutide 2.4, and patients without diabetes, but, again, we won't have those data probably for a couple of years. I also think there is a cardiovascular outcomes trial in process for patients with diabetes for tirzepatide. Again, we're just awaiting those data, but if we can show that these medications, together with lifestyle interventions, achieved sufficient weight loss to put them in the range where we can expect to see cardioprevention, that could be and that should be a game-changer.

I think in terms of how we think about these patients, we need to help increase the access of patients to these evidence-based therapies, which currently for obesity is somewhat limited. Maybe, with these data showing the degree of weight loss, how this weight loss translates in to the prevention, or treatment of obesity related complications, I think payers and healthcare systems are going to be more amenable to making these therapies these interventions available to patients.

Hiddo Heerspink, PharmD, PhD: I think it's time to think about prevention of complications of type 2 diabetes or prediabetes. Metformin is a fantastic drug to reduce hyperglycemia, but the outcome data, as you mentioned, is limited. We have fantastic outcome data with SGLT2 inhibitors and fantastic outcome data with GLP-1 receptor agonists.

So, from my perspective, it's really time to rethink our approach for the treatment and the sequencing of tracks. As I've already mentioned, I believe it's about the prevention of outcomes. It's not also prevention of diabetes or new-onset diabetes and we have data from the SGLT2 trials with nondiabetic patients that SGLT2 inhibitors reduced new onset diabetes by over 33%.

So, it's really important to take that into consideration and rethink our approach. Our approach has been traditionally on the timing of when drugs came to market and we have always added all new drug but now with many new drugs showing cardiovascular benefits, it's time to think about which combination for which patients. So, we are really heading into an area of personalized medicine I've received the near future.

These transcripts have been edited for length and clarity.

Original post:
Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network

DCISionRT with Novel Residual Risk Subtype Identifies Patients Who May Not Benefit from ET after Surgery and Radiation

LAGUNA HILLS, Calif., June 7, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL.

The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET.

"For the first time, physicians have access to an enhanced method of identifying which patients may have a significant or minimal benefit from adjuvant endocrine therapy based on individual tumor biology," said Pat Whitworth, MD, FACS, ASCO Presenter and Breast Surgical Oncologist Director, Nashville Breast Center; Associate Professor, University of Tennessee; and Managing Partner TME. "The results are meaningful and support a more tailored treatment plan for our DCIS patients."

DCISionRT stratified patients as low risk, neither adjuvant ET nor radiation therapy (RT) resulted in reduced 10-year ipsilateral breast recurrence (IBR) (5.6% BCS+ET vs BCS alone). Patients in the elevated risk group, benefited from adjuvant ET as well as RT.

"We are excited to share this unique data demonstrating the expanded utility of DCISionRT to guide personalized treatment decisions for DCIS patients," says Dan Forche, President and CEO of PreludeDx. "As precision medicine becomes the new standard of care, we are committed to continuous innovation to improve healthcare outcomes for early-stage breast cancer patients, clinicians and the healthcare system."

About DCISionRT for Breast DCIS

DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Scorethat identifies a woman's risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk. PreludeDx is a Fjord Ventures portfolio company.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact

Investor Contact

Cory Dunn

Andrew Wade

760.705.7464

949.600.8925

cdunn@preludedx.com

awade@preludedx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/preludedx-presents-new-dcisionrt-data-on-the-effectiveness-of-endocrine-therapy-in-dcis-patients-at-the-asco-2022-annual-meeting-301562715.html

SOURCE PreludeDx

View post:
PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV

Hyderabad, June 6 (UNI) Technology Business Incubator Birla Institute of Technology and Science (BITS) Pilani, Hyderabad has collaborated with American Association for Precision Medicine (AAPM) and World Investors and Entrepreneurs Summit (WISE) to conduct the 'Precision Medicine 2022' event at its campus here on Tuesday with the theme of Precision Medicine, Artificial Intelligence (AI) & the Future of Personalized Health care.This event brings together top experts and thought leaders in precision medicine, life science, biotech, MedTech, and pharma. It is designed to bring the community together and serve as a leading forum for new medical breakthroughs and cutting-edge basic, translational, and clinical research, BITS Pilani said in a release here on Monday.

To fulfill this vision, we will be showcasing thought leaders involved in innovative research, developing new capabilities, and developing technological interventions to speed up the delivery of personal health. The biggest Precision Medicine event will also showcase new solutions to clinical and omics data collection, transfer, storage, analysis, security, and design/implement new Big Data Solutions and AI.UNI KNR CS1206

Here is the original post:
BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India

ReportLinker

Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares. - Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Laboratory Information Systems (LIS) Industry" - https://www.reportlinker.com/p05957217/?utm_source=GNW - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass Research Platform - Complimentary updates for one year - Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026

- LIS is advanced software that stores and manages data in laboratories, and is used for sending test orders, recording laboratory test results, sorting data in databases. These platforms are widely used by clinics, hospitals and diagnostic laboratories to maintain data related to tests and medical history of patients, track data quality and send laboratory test orders. The demand for LIS is driven by their ability to enhance productivity, allow precise and accurate diagnosis, reduce diagnostic errors and improve patient satisfaction. The global market is poised to register significant growth in the future due to various factors such as rising incidence of chronic diseases, the huge volume of test data obtained from clinical testing, the need for enhanced lab automation and efficiency. The global market for these systems is also propelled by increasing adoption of digital solutions to store, retrieve and maintain data in real-time. These systems are offered by sophisticated analytic tools to deal with healthcare issues and improve overall productivity. The market is gaining from the need to reduce diagnostic errors, use of LIS to boost laboratory workflow efficiency, and incorporation of these systems with EHR systems. However, factors such as high maintenance cost, shortage of skilled professionals, and need for specialized laboratories remain key challenges for the market. On the other hand, huge investments by governments in LIS, increasing need for customized systems with data security functions and availability of advanced platforms are expected to present new growth avenues for the market. Rising adoption of laboratory automation and advances in R&D, particularly in biotechnology and pharmaceutical industries, are slated to push the market growth.

- Amid the COVID-19 crisis, the global market for Laboratory Information Systems (LIS) estimated at US$1.7 Billion in the year 2022, is projected to reach a revised size of US$2.4 Billion by 2026, growing at a CAGR of 9.2% over the analysis period. Standalone, one of the segments analyzed in the report, is projected to grow at a 6.6% CAGR to reach US$1.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Integrated segment is readjusted to a revised 12.2% CAGR for the next 7-year period. This segment currently accounts for a 41.9% share of the global Laboratory Information Systems (LIS) market. Based on product, standalone LIS segment is poised to hold a major share of the market during the analysis period, owing to key factors such as user-friendly nature, enhanced data security, affordability, and ability to work offline. As standalone LIS are not part of a software package, their ability to work offline augments its implementation. Technological innovations is also expected to further boost demand for standalone LIS. Integrated LIS is projected to witness faster growth during the analysis period. Against a backdrop of rising adoption of EMR, healthcare institutions are striving to achieve interoperability and standardization. This in turn spurred the shift from best-of-breed or standalone LIS to deployment of enterprise-wide integrated LIS. Integrated LIS lower dependencies on interfaces, vendor contracts, and total cost of ownership. The U.S. Market is Estimated at $825.5 Million in 2022, While China is Forecast to Reach $148.5 Million by 2026

- The Laboratory Information Systems (LIS) market in the U.S. is estimated at US$825.5 Million in the year 2022. The country currently accounts for a 52.9% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$148.5 Million in the year 2026 trailing a CAGR of 12.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR while Rest of European market (as defined in the study) will reach US$166.8 Million by the close of the analysis period. The US is at the forefront of adoption of LIS systems and dominates the global market, owing to favorable reimbursement policies in the country, for pathology procedures. The region is exhibiting strong gains on account of technological advancements and expansion of the healthcare sector, encompassing clinical research laboratories and diagnostic centers. Europe is another lucrative market for LIS. Developed countries like Germany for instance, are increasingly embracing automation in healthcare for reducing need for workforce. Healthcare providers in such markets are eagerly focusing on deploying automation like LIS for providing quality care to patients. The LIS market in Asia-Pacific, mainly China, is projected to post the fastest growth rate in the coming years due to extensive penetration of these systems in the region on account of surge in personalized medicine demand in the country and also rapid propagation of cloud LIS. Select Competitors (Total 254 Featured) Cerner Corporation Cirdan Comp Pro Med, Inc. CompuGroup Medical AG Margy Tech Pvt Ltd. McKesson Corporation Meditech Orchard Software Corporation Soft Computer Consultants Inc. Sunquest Information Systems, Inc. XIFIN Inc.

Read the full report: https://www.reportlinker.com/p05957217/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession The Never-Ending ?Race? Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond? Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine Efficiency Against New Strains? With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them? EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021 With IMF Making an Upward Revision of Global GDP for 2022, Companies Are Bullish About a Continuing Economic Comeback Despite a Prolonging Pandemic EXHIBIT 3: A Strong Yet Uncertain Recovery Shaped by New Variants Comes Into Play: World Economic Growth Projections: (Real GDP, Annual % Change) for 2020 through 2022 Overwhelming COVID-19 Testing Volumes Elevate Demand for Laboratory Information Systems EXHIBIT 4: Laboratory Information Systems (LIS) - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for 254 Players Worldwide in 2022 (E) A Prelude to Laboratory Information Systems (LIS) Functions of an Effective LIS Global Laboratory Information Systems Market to Witness Rapid Growth Standalone LIS Holds Major Share Services Segment Dominates the LIS Market, Software to Witness Higher Growth during the Forecast Period On-Premise LIS Holds Major Share Due to Customization Benefits Cloud-based LIS Model to Grow in Prominence due to Many Benefits Offered over Traditional, On-Premise Models US Holds Clear Edge over Other Regions, Asia-Pacific to Exhibit Fastest Growth RECENT MARKET ACTIVITY

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS Introduction of Advanced Technologies Fuel Demand for Laboratory Information Systems Digitization of Healthcare Drives Integration of LIS Accelerating Pace of Digital Pathology Increase Adoption Increasing Concerns Pertaining to Data Integrity Fuel Demand for Laboratory Information Systems Introduction of Stringent Data Protection Guidelines Propel Demand for Laboratory Information System Software Use of Easy to Integrate Laboratory Information Systems Gain Momentum Artificial Intelligence Gains Prominence EXHIBIT 5: AI Spending in Healthcare & Life sciences in US$ Million for Years 2020 & 2025 Burgeoning Population and Rising Incidence of Chronic Diseases: A Key Market Driver for LIS EXHIBIT 6: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Cancer Site: 2020 EXHIBIT 9: Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for Laboratory Information System/LIS market EXHIBIT 10: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 Growing Adoption of Laboratory Automation Drives the Need for LIS Rise of Laboratory 4.0 to Spur the Adoption of LIS EXHIBIT 11: World Laboratory Automation Market in US$ Billion for Years 2018, 2020, 2022, 2024 & 2026 Laboratory Information Systems Gain Traction amidst Growing Need to Enhance Workflow Efficiencies and Reduce Costs Rise in Molecular Testing Volumes to Elevate Demand EXHIBIT 12: Global Genetic Testing Market in US$ Million: 2015, 2020, & 2025 Improving Healthcare Expenditure to Turbo Charge Future Growth of the Market EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 EXHIBIT 14: Elderly Healthcare Expenditure as a % of GDP Need to Improve Diagnostics Accuracy Increasing Popularity of Enterprise LIS Rise in Consolidation of Healthcare Providers Creates Need for Robust and Comprehensive LIS Growing Emphasis on Personalized Medicine to Support Growth EXHIBIT 15: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025 Rise in Investment in R&D Activity to Spur Growth Shortage of Trained Professionals Hinders Adoption Rate

4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Laboratory Information Systems (LIS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Standalone by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Integrated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Integrated by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for On-Premise by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for On-Premise by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Cloud by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Cloud by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospital Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospital Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Independent Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) Market Analytics Table 31: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 40: USA Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CANADA Table 43: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 52: Canada Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

JAPAN Table 55: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 58: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 61: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 64: Japan Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

CHINA Table 67: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 70: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

Table 73: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Component - Services and Software - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Laboratory Information Systems (LIS) by Component - Services and Software Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Laboratory Information Systems (LIS) by Component - Percentage Breakdown of Value Revenues for Services and Software for the Years 2012, 2021 & 2027

Table 76: China Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: China Historic Review for Laboratory Information Systems (LIS) by End-Use - Hospital Laboratories, Independent Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Laboratory Information Systems (LIS) by End-Use - Percentage Breakdown of Value Revenues for Hospital Laboratories, Independent Laboratories and Other End-Uses for the Years 2012, 2021 & 2027

EUROPE Laboratory Information Systems (LIS) Market Presence - Strong/ Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) Market Analytics Table 79: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Laboratory Information Systems (LIS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 82: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Product - Standalone and Integrated - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Laboratory Information Systems (LIS) by Product - Standalone and Integrated Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Product - Percentage Breakdown of Value Revenues for Standalone and Integrated for the Years 2012, 2021 & 2027

Table 85: Europe Recent Past, Current & Future Analysis for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Laboratory Information Systems (LIS) by Deployment - On-Premise and Cloud Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Laboratory Information Systems (LIS) by Deployment - Percentage Breakdown of Value Revenues for On-Premise and Cloud for the Years 2012, 2021 & 2027

The rest is here:
Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance

Medical Nutrition Market: Complementarity of Pharmacology & Nutrition to Augur Well for Growth

As old health rules are overturned, a physiological approach that starts from health in place of disease is gaining high emphasis. Hippocrates quote, Let food be thy medicine and medicine be thy food has been put into practice, as individuals are considering medical nutrition and food for enhancing health and treating disease, despite the developments procured in the field of medical science.

Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1704

The idea of disease prevention to avoid or simplify complicated therapeutics is supported by the convergence of the pharmaceutical and food industry. In the past years, literatures have stated that the gap between nutrition science and pharmacology has been narrowing, a progress stirred by both disciplines. The only substances considered pharmacologically active in the past were drugs. Progressing on these terms, medical nutrition, the new treatment pattern entails on the fact that nutrients can have an intense effect on metabolic, immunological and other pathophysiological processes of unhealthy patients.

TMR, in its new research study, reveals compelling insights into the medical nutrition space, to assist readers with data-driven decision making. According to the TMR study, revenues from the medical nutrition market closed in on a valuation of over US$ 13,000 Mn in 2018. This growth is attributed to the growing awareness of chronic diseases among consumers coupled with the various initiatives and programs commenced for the effective prevention and control of these diseases. This has led to the growing inclination towards medical nutrition supplements.

Developments in biotechnology has further resulted in the revolution of the medical nutrition market as key manufacturers are concentrating on research and development of improved and personalized medical nutrition offerings. Moreover, the development of disease-specific specialized solution for the medical nutrition markets is also observed, particularly in the developed economies.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1704

From industry giants to first-movers, enterprises have long been in mercy of revolutionizing industry trends. Key trends shaping the medical nutrition landscape are discussed below.

Get COVID-19 Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1704

The digestive wellness trend embodies the increasing awareness around new ingredients, nutritional products which are based on the public health recommendations and science. This is led to the reduction of sugar content of foods. According to reports, a large part of the consumer base prefers the consumption of health-improving ingredients through food, as consumers care about nutrition with which they gain a control over their health and lifestyle. Foods that help reduce the gastrointestinal symptoms including the free-from foods, added-benefits ingredients,fermented foods, prebiotics, andprobioticsare gaining focus with this trend.

Driven by key developments in technology along with the continual progress attained by the field of science, the personalized medical nutrition has become much more than just a concept. Medical nutrition solutions providers are incorporating multidisciplinary approach to set up centers that focus on development of nutritional products that cater to specific needs. The future of personalized medical nutrition is cited to be fully individualized backed with constant monitoring of personalized information including gut bacteria, biomarkers or genes.

Explore More Related Reports:

Vegetable Oils Market https://www.transparencymarketresearch.com/vegetable-oil-market.htmlHerbal Extracts in Nutraceuticals Market https://www.transparencymarketresearch.com/herbal-extracts-in-nutraceuticals-market.htmlMoringa Supplements Market https://www.transparencymarketresearch.com/moringa-supplements-market.htmlChelated Minerals Market https://www.transparencymarketresearch.com/chelated-minerals-market.htmlLivestock Cake Market https://www.transparencymarketresearch.com/livestock-cake-market.html

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision

Contact:

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email:[emailprotected]Website:https://www.transparencymarketresearch.com/

View post:
Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal

Published on June 7, 2022

Bengaluru: A new whitepaper, commissioned by Lenovo & Intel, led by IDC, highlights key challenges and drivers transforming the healthcare landscape across Asia Pacific. Titled Leveraging High-Performance Compute Infrastructure to Address the Genomic Data Challenge in Life Sciences, the paper underlines humanitys greatest challenges where genomics research-led intervention could impact significantly. A key highlight from the paper states that while the pandemic-led acceleration in innovation has given a boost to the Indian healthcare sector, genomics high-performance computing (HPC) infrastructure that is key to drug/vaccine discovery & precision medicine, is still at a startup stage for nearly 57% of surveyed organizations in India. This trend is also seen across a few other APAC regions surveyed: Japan and Korea lead in having advanced (3+ years) infrastructure.

The survey was conducted across 150 pharmaceutical and biotech companies across five key markets in Asia India, Singapore, Thailand, Japan, and Korea.

Genomics and Humanitys Greatest Challenges:

When it comes to solving biggest challenges facing societies and mankind, 40% of decision makers in India are certain that genomics is fundamental to developing a precision medicine strategy to treat chronic illness, rare diseases, and lifestyle disorders. Unsurprisingly, 33% of the organizations surveyed across Asia Pacific mirror this drift, followed by 21% who believe genomics can improve development of drugs and vaccines which is also a priority for 20% organizations in India.

Distinctive aspects discovered in the white paper point to the expansive potential of genomics. One being able to impact hunger and malnutrition, which has been ranked as the second greatest challenge across 40% of decision makers. According to 30% of surveyed leaders in India, genomics could also be a game-changer in helping to improve the environment as climate change continues to be a serious cause of concern.

Commenting on this, Sinisa Nikolic, Director and Segment Leader, HPC & AI, AP, Lenovo ISG, said, The volume and type of genomics data generated is unimaginable and to make accurate decisions based on this data requires huge computing power. This gets even more difficult with complex and unscalable solutions that were found to be cautious factors for 50% of organizations in India looking for genomics solutions.

Increasing Genomic Workloads and Storage Capabilities:

The trend towards developing niche, high-value personalized health solutions is expected to boom as 83% of organizations in India anticipate their annual genomics workloads to grow more than 10% over the next two years. Similarly, for 80%, the annual spend on data storage and compute is likely to increase more than 10% in the two-years period.

Sumir Bhatia, President AP, Lenovo ISG, said, One size doesnt fit all, whether at frontend healthcare delivery or backend IT infrastructure. To catchup with the ever-growing data, the required infrastructure setup can immensely add to the capital and operational expenditure. We expect this to be a critical challenge for organizations in India working to enhance their HPC infrastructure. This is where pay-as-you-go models like Lenovo TruScale become crucial so businesses of all sizes can scale up & down as required, and easily manage their operational expenditure to address humanitys greatest challenges.

The growing storage requirement predictions could add to the existing cost burdens for 33% of organizations who are currently spending more than $1M annually on data compute, storage, and maintenance & services. Even with the challenges around scalability, flexibility, and costs, nearly half (46.7%) of the respondents are not looking to acquire new solutions to transform their HPC landscape. Surprisingly, similar feedback was given by 50 percent of the leaders in Asia.

Recognizing IT Challenges and Accelerating Genomics Transformation with HPC:

With a growing focus on making precision medicine a reality, nearly 47% of decision-makers in Indias genomics industry feel that, with the high velocity at which genome data is generated, the lack of computing power to analyze it becomes the biggest infrastructural challenge for genome sequencing. Delving further into the challenges, 40% of the respondents ranked multi-dimensionality of data as the second-big IT challenge.

Close to 97% of respondents in India are using high-performance workstations and nearly 23% also use laptops for data visualization. Interestingly, 46% are using 3D augmented reality/virtual reality (AR/VR) solutions, indicating a growing shift toward immersive visualization techniques, complemented by deep learning to enable molecular modeling and simulations.

A major challenge for researchers is the time taken to process a single genome. Fortunately, solutions like Lenovo Genomics Optimization and Scalability Tool (GOAST) reduce the time to process a single human genome from 150 hours to less than 48 minutes. This enables researchers to quickly map a cohort of people instead of spending time analyzing a single genome. HPC supports high-throughput volumes to accelerate the speed of analysis, whereas AI helps make sense of the difference between genomes. This is why we are seeing GOAST being preferred by nearly 37% of organizations in India and expecting it to grow tremendously over the next few years. Sinisa Nikolic added.

In the entire context of genomics data, cyberthreats are a key challenge for only 3% of the organizations in India, while more than 80% feel strongly of their cybersecurity strategy indicating it as lowest amongst the hurdles.

Go here to read the rest:
57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

myCare-024-04 Study Finds Cellworks Personalized Biosimulation Provides Superior OS and PFS Predictions for GBM Patients Beyond Standard Clinical Factors

CHICAGO--(BUSINESS WIRE)--

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-024-04 study, which demonstrate that the Cellworks Singula Therapy Response Index (TRI) was strongly predictive of Overall Survival (OS) and Progression-Free Survival (PFS) for newly diagnosed Glioblastoma Multiforme (GBM) patients. In this study, Singula TRI provided patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies and provided predictive value beyond physician-prescribed therapy, patient age, patient sex, and MGMT methylation status.

The results from the myCare-024-04 clinical study were featured in a poster presentation with comments from Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida, at the 2022 ASCO Annual Meeting June 3-7th during the Central Nervous Systems Tumors Session and available online as Abstract 2053.

The molecular heterogeneity of GBM is a key driver for the inconsistent therapy response rates that we see in brain cancer patients and makes the disease difficult to treat, said Patrick Wen, MD, Director, Center for Neuro-oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; and Co-Principal Investigator for the myCare-024-04 clinical study. But by using a patients NGS data and Cellworks Singula to biosimulate their individual therapy responses, we can potentially improve the ability to select the most effective therapy for each GBM patient and positively effect clinical outcomes for brain cancer patients.

The significant differences in treatment response among GBM patients necessitates moving beyond population-based treatments to personalized multi-gene therapy predictions, said Dr. Manmeet Ahluwalia, M.D., M.B.A., Chief of Medical Oncology, Chief Scientific Officer and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida; and Co-Principal Investigator for the myCare-024-04 clinical study. Using Cellworks Singula TRI, we can simulate the molecular effects of cell signaling, drugs and radiation on patient-specific in silico diseased cells prior to treatment and then identify the magnitude of disease control and survival for specific anti-tumor strategies. The findings from using this approach in the myCare-024-04 study suggest that biosimulating guideline GBM therapies for newly diagnosed GBM patients can positively effect clinical outcomes.

The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. The platform is powered by the groundbreaking Cellworks Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks CBM. The Cellworks platform analyzes the impact of specific therapies on the patients personalized disease model and generates a Singula biosimulation report with Therapy Response Index (TRI) scores from 0 to 100 that predict the efficacy of specific chemotherapies.

myCare-024-04 Clinical Study

Background

In this study, the Cellworks Singula Therapy Response Index (TRI) was used to prospectively predict the Overall Survival (OS) and Progression-Free Survival (PFS) in a retrospective cohort of 270 IDH wildtype GBM patients from the Cancer Genome Atlas (TCGA) with known clinical outcomes treated with physician prescribed therapies. The cohort included 162 males and 108 females with a median age of 57.5 years.

Methods

A mechanistic mulit-omcis biology model created for each patient using comprehensive genomic inputs allows biosimulation of downstream molecular effects of cell signaling, drugs and radiation on a patients personalized in silico disease model. Stratified random sampling was used to split the data into independent training (N=153) and validation (N=117) subjects. Multivariate Cox Proportional Hazard and Proportional Odds models were used to model OS and PFS as a function of the pre-defined Singula TRI and clinical thresholds. Cox Proportional Hazards (PH) regression and likelihood ratio (LR) tests were used on the independent validation subjects to assess the hypothesis that Singula is predictive of OS and PFS above and beyond standard clinical factors.

Results

Using Cellworks Personalized Therapy Biosimulation, Singula TRI was significantly predictive of OS and PFS in univariate analyses and remained significantly predictive in multivariate analyses, which included patient age, patient sex, MGMT methylation status and drug class.

Conclusions

Cellworks Singula TRI facilitates selection of optimal personalized therapies by providing patient-specific estimates of OS and PFS for 18 NCCN guideline GBM therapies. This information may be used to estimate increases in OS and PFS when comparing Singula TRI recommended therapies verses standard care. These positive results suggest the utility of biosimulation-informed therapy selection to improve survival of GEA patients.

About Cellworks Group

Cellworks Group, Inc. is a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology. Using innovative multi-omics modeling, computational biosimulation and Artificial Intelligence heuristics, Cellworks predicts the most efficacious therapies for patients. The Cellworks unique biosimulation platform is a unified representation of biological knowledge curated from heterogeneous datasets and applied to finding cures. Backed by UnitedHealth Group, Sequoia Capital, Agilent and Artiman, Cellworks has the worlds strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software technologists working toward a common goal attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California and has a research and development facility in Bangalore, India. For more information, visit http://www.cellworks.life and follow us on Twitter @cellworkslife.

All trademarks and registered trademarks in this document are the properties of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005437/en/

Barbara ReichertReichert Communications, LLC[emailprotected]415-225-2991

Michele Macpherson, Chief Business OfficerCellworks Group, Inc.[emailprotected]650-346-9980

Source: Cellworks Group, Inc.

Original post:
Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com

The forums at analytica invite visitors to practical presentations and panel discussions.

Live in Munich again at last: When analytica, the worlds leading trade fair for laboratory technology, analysis and biotechnology, opens its doors from June 21 to 24, around 900 exhibitors will present their innovations. The industry is particularly looking forward to in-person dialog. There are ample opportunities for this at the trade fair stands, as well as at the analytica conference, in the forums and during the many other accompanying events. Nothing beats a real get-together, says Armin Wittmann, Exhibition Director for analytica. The attractive analytica supporting program brings the laboratory of tomorrow to life and facilitates the exchange of know-how, experience and ideas.

The analytica conference, the scientific high point of analytica, will take place on the first three days of the trade fair in the ICM, right next to the exhibition halls. Whether its nanoplastics, cancer diagnosis or antibiotic-resistant germs in the water cycle: In nearly 200 presentations and a poster show, renowned scientists from all over the world will discuss what modern analytics is capable of today, where its limits currently lie and how these can be overcome in future. The multifaceted program was put together by the German Chemical Society (Gesellschaft Deutscher Chemiker, GDCh), the German Biochemistry and Molecular Biology Society (Gesellschaft fr Biochemie und Molekularbiologie, GBM) and the German Society for Clinical Chemistry and Laboratory Medicine e.V. (Deutsche Vereinte Gesellschaft fr Klinische Chemie und Laboratoriumsmedizin, DGKL).

The megatrend of digitalization will be a common thread through the analytica conference program, as well as through the exhibition halls. In the Digital Transformation special show in Hall B2, visitors can experience automated workflows, networked devices and robots in action. In the neighboring forum of the same name, Agilent, Merck, Mettler Toledo, Thermo Fisher Scientific and many other companies will explain their concepts for Laboratory 4.0 in 30-minute presentations. The industry association SPECTARIS will provide an overview of the current status of a uniform OPC-UA interface for German manufacturers.

The Biotech forum (Hall A3), the Occupational Health and Safety forum and the analytica forum (both in Hall B1) likewise invite visitors to practical presentations and podium discussions. Among the highlights in the analytica forum are the expert rounds on COVID-19 research on June 22 and 23, with the likes of Professor Jonas Schmidt-Chanasit from the Bernhard Nocht Institute for Tropical Medicine in Hamburg and Professor Helga Rbsamen-Schaeff, Leopoldina member and founder and Supervisory Board member of the biopharmaceutical company AiCuris. The exact dates will be announced shortly on the analytica website.

The German biotech industry has emerged as a solution to problems during the pandemic and has collected more capital in the past two years than ever before. The Finance Days on June 23 and 24 at the Biotech forum in Hall A3 will cover financing trends in the life sciences sector and answer questions about initial public offerings and global markets. With the personalized medicine themed day on June 24, analytica is also putting a particular focus on this promising sector. Representatives from associations, clusters and companies in the health care sector will discuss the potential of individualized therapies from various perspectives.

Safety in the laboratory is the number one priority in day-to-day work. The Occupational Health and Safety forum in Hall B2 will be devoted to this topic. This year at analytica, the company asecos will once again demonstrate accidents that can happen if hazardous substances are stored incorrectly in the laboratory live in their daily experimental presentations. There will also be presentations on lithium-ion batteries that are increasingly finding their way into laboratories and whose potential dangers should they be mishandled are often underestimated. The program is rounded out by presentations from companies such as Erlab, Bernd Kraft and a1-environsciences.

Anyone who wants to use analytica as a career booster can combine a trade fair visit with further training. The training and consulting firm Dr. Klinkner & Partner will be offering all-day seminars at analytica on selected topics, from laboratory IT to the validation of analytical methods. And last but not least analytica, together with the scientific society GDCh and the VBio, will be supporting young talent in the industry. As usual, the popular student information day will take place on the last day of the trade fair on June 24. Here, high-school graduates can learn about fields of study and occupational areas in chemistry, biotechnology and food chemistry.

Read more from the original source:
Inspiration for the laboratory of tomorrow - Chemie.de

MarketQuest.biz latest record at the Global Nanomaterials in Personalized Medicine Market is predicted to experience excessive growth from 2022 to 2028. The report is an in-depth analysis of a wealthy supply of main factors liable for developing the global Nanomaterials in Personalized Medicine market. The study has captured several factors that have had or are having a substantial influence on the industry. The data factors like the drivers, flow patterns, openings, restrictions, and information are gathered through actual sources for plans for the Nanomaterials in Personalized Medicine market.

The Report Consists of:

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/125574

The report focuses on the studies of earlier and contemporary market attributes, which form a basis for evaluating the possibilities of the industry. The study assists in the identification of new marketing possibilities & provides a comprehensive view of the current global Nanomaterials in Personalized Medicine market. The record offers company profile of the key vendors operating in the Nanomaterials in Personalized Medicine industry and comparative analysis based on their business product offering, overviews, segment market share, business strategies, regional presence, innovations, joint venture, M&A, SWOT analysis, recent developments, collaborations, partnerships, and key financial information.

The worldwide Nanomaterials in Personalized Medicine market research is divided into categories that include

The global Nanomaterials in Personalized Medicine market study is classified into applications that cover

Some of the most promising vendors include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/125574/global-nanomaterials-in-personalized-medicine-market-2022-by-company-regions-type-and-application-forecast-to-2028

The regional segments of the market include:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketquest.biz

View original post here:
Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia...

ReportLinker

In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report. Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients.

New York, May 02, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomarkers Market - Global Outlook & Forecast 2022-2027" - https://www.reportlinker.com/p06272725/?utm_source=GNW Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.

The global biomarkers market is expected to grow at a CAGR of 11.44%.

KEY HIGHLIGHTS

Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focussing on identifying biomarkers to provide healthcare system solutions to them. Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinsons and Alzheimers disease and clinical outcome assessments. Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers. Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.

GROWTH ENABLERS

Increase In Number of Pipeline Biomarkers Rising Adoption of Biomarkers In Disease Diagnostics Technological Advancements in Biomarker Discovery

GLOBAL BIOMARKERS MARKET SEGMENTATION Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.

Segmentation by Indication Oncology Cardiology Neurology Immunology Others

Segmentation by Application Diagnostics Drug Discovery & Development Personalized Medicine (PM) Others

Segmentation by Type Diagnostic Biomarker Monitoring Biomarker Prognostic Biomarker Susceptibility Biomarker Other Biomarker

VENDOR ANALYSIS Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.

Key Vendors

Abbott company BioMerieux Biohit OYJ CENTOGENE Creative Diagnostics F. Hoffmann-La Roche company Fujirebio General Electric (GE) company TAmiRNA

Other Prominent Vendors

Accure Therapeutics Agilent Almac Group Applied Research Using OMIC Sciences (AROMICS) Bio-Rad Laboratories BioVision Caris Life Sciences Denovo Biopharma Dreamgenics Eisai Epigenomics Immunovia Insilico Medicine Lexogen Monument Tx Oryzon Genomics Plexision Rules-Based Medicine Siemens Healthineers Second Genome Therapeutics Thermo Fisher Scientific Ymir Genomics

GEOGRAPHICAL ANALYSIS North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.

Segmentation by Geography

North America o US o Canada

Europe o Germany o France o UK o Italy o Spain

APAC o Japan o China o India o South Korea o Australia

Latin America o Brazil o Mexico o Argentina

Middle East & Africa o Turkey o South Africa o Saudi Arabia

THE REPORT INCLUDES: 1. The analysis of the global Biomarkers market size and growth rate for the forecast period 2022-2027. 2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global Biomarkers market. 3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities. 4. It offers a complete overview of market segments and the regional outlook of the Biomarkers market.Read the full report: https://www.reportlinker.com/p06272725/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to see the original:
The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance

Bioinformatics Marketis valued atUSD 10.82 Billion in 2021and is expected to reachUSD 24.07 Billion by 2028with aCAGR of 12.1%over the forecast period.

The increasing scope in research and development, drug discovery, new advancements in genetics analysis and synthesis methods and techniques are driving the Bioinformatics market.

The healthcare sector has seen a development in the last couple of years with the coronavirus pandemic hurting the world in the hardest ways possible and changing the way people live forever. Healthcare has been the topic of discussions at the macro and micro levels and manufacturers have realized that it is time for them to invest in technology and come up with innovative ways to help people. They get funded extensively with the government initiatives too as the authorities all over the world create commissions to help the healthcare sector. The research initiatives take time and multiple rounds of investment but in the interest of the people at large they make sure that those requirements are met. Bioinformatics market in healthcare depends a lot on how innovative the advancements are and how they are used in the long run as the lock in period is always going to be long.

A trend which is aiding Bioinformatics market in healthcare is the habits of people which are increasingly becoming unhealthier. People, particularly in the developing countries live a life where they work really hard and they do not have the time to focus on their health. That is why there is a rise in number of obesity and other diseases in the world. With technological advancements, many illnesses can be diagnosed before they become serious ailments. Diabetes is a common illness which can now be tapped by checking the blood sugar levels at home through advancements of technology. The technological advancements in Bioinformatics market in healthcare can also help people get healthcare services remotely. It is difficult particularly in the developing nations to manage time for their healthcare requirements. This has increased the prevalence of illnesses that made the world look at innovative ways to come up with solutions. In the pandemic, we saw that testing kits played a key role in preventing the spread of the pandemic.

Download Free Exclusive Sample (200 Pages PDF) Report @ :

https://brandessenceresearch.com/requestSample/PostId/1221?utm_source=nandini&utm_medium=mn

Some major key players for global Bioinformatics market are,

Bioinformatics market in healthcare has now seen its future vision and how the world will operate once the pandemic is over. Technology is going to play a key role in how the world moves forward. The challenges are going to increase only with the eating habits increasingly becoming worse. Healthcare sector has also been focusing on the mental health aspect. There are innovative ways where counseling can be given online with the use of technology. Governments are also focusing on finding means of e-healthcare in order to benefit people remotely. E-healthcare has also been aided by the accessibility of social media to the deepest part of countries.

The growth of literacy and awareness is also helping people get their consultancy online. The COVID pandemic showed the world ways in which adoption of technology can be the key to how countries deal with healthcare emergencies. Another factor which is aiding growth is how the insurance is extending its wings to the online consultancy too. This will continuously aid the initiatives of online consultancy and help the healthcare sector see growth in the coming years. Bioinformatics market in healthcare surely has a future which will depend on technological advancements

Bioinformatics Market: Key Features

The report throws light on the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the Bioinformatics market. Bioinformatics Market Size, Growth Analysis, Industry Trend, and Forecast, offers details of the factors influencing the global business scope. This report provides future products, joint ventures, marketing strategy, developments, mergers and acquisitions, marketing, promotions, revenue, import, export, CAGR values, the industry as a whole, and the particular competitors faced are also studied in the large-scale market.

Bioinformatics Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The data points provided are only related to the companys focus related to Bioinformatics market. Leading global Bioinformatics market players and manufacturers are studied to give a brief idea about competitions.

Latest news and industry developments in terms of market expansions, acquisitions, growth strategies, joint ventures and collaborations, product launches, market expansions etc. are included in the report. The report focuses on the operation and their competitive landscape present within the market. Identification of numerous key players of the market will help the reader perceive the ways and collaborations that players will need to understand the competition within the global Bioinformatics market.

Bioinformatics Market report provides depth analysis of the market recent developments and comprehensive competitive landscape created by the COVID19/CORONA Virus pandemic. Bioinformatics Market report is helpful for strategists, marketers and senior management, And Key Players in Bioinformatics Industry.

Market Dynamics Of Bioinformatics Market

Global Bioinformatics market report has the best research offerings and the required critical information for looking new product trends or competitive analysis of an existing or emerging market. Companies can sharpen their competitive edge again and again with this business report. The report comprises of expert insights on global industries, products, company profiles, and market trends. Users can gain unlimited, company-wide access to a comprehensive catalog of industry-specific market research from this industry analysis report. The market report examines industries at a much higher level than an industry study.

Table of Content: Global Bioinformatics Market Research Report

Chapter 1: Global Bioinformatics Industry Overview

Chapter 2: Global Economic Impact on Bioinformatics Market

Chapter 3: Global Market Size Competition by Industry Producers

Chapter 4: Global Productions, Revenue (Value), according to Regions

Chapter 5: Global Supplies (Production), Consumption, Export, Import, geographically

Chapter 6: Global Productions, Revenue (Value), Price Trend, Product Type

Chapter 7: Global Market Analysis, on the basis of Application

Chapter 8: Bioinformatics Market Industry Value Chain

Chapter 9: Bioinformatics Market Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10: Strategies and key policies by Distributors/Suppliers/Traders

Chapter 11: Key Economic Indicators, by Market Vendors

Chapter 12: Market Effect Factors Analysis

Chapter 13: Global Bioinformatics Market Forecast Period

Chapter 14: Future Of The Market

Chapter 15: Appendix

Substantial research & development activities carry out by some players that comprises offering training to covering recent information on new technology, materials and techniques to innovative practice solutions, will complement the market growth is also explained. Frequent technological advances, superior portability, and ease of handling for Bioinformatics are boosting adoption in home and alternate care settings as well. Furthermore, non-profit and government initiatives, and awareness programs, and an influx of funding for research studies have positively influenced developments within the industry.

Global Bioinformatics Market: Regional Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2022 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact Us:

Contact No.: +91 7447409162, +44-2038074155, 1-888-853-7040

Email: sales@brandessenceresearch.com

Related Report

TheSilicon Photonics Market Valueis expected to record a valuation ofUSD 7253.6 Millionby 2028, Registering to Accelerate at a 25.8% CAGR, According to the most recent study by Brandessence Market Research & Consulting Pvt ltd.

TheAutomotive Diagnostic Scan Tools MarketValue is expected to record a valuation ofUSD 46.17 Billionby 2028, Registering to Accelerate at a 5.2% CAGR, According to the most recent study by Brandessence Market Research & Consulting Pvt ltd.

TheCRM Software Market Sizeis expected to record a valuation ofUSD 100.63 Billionby 2028, Registering to Accelerate at a 12.34% CAGR, According to the most recent study byBrandessence Market Research & Consulting Pvt ltd.

TheFrozen Potato MarketValue is expected to record a valuation ofUSD 81.69 Billionby 2028, Registering to Accelerate at a 4.12% CAGR, According to the most recent study by Brandessence Market Research

Originally posted here:
Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular...

Melanie Street calls COVID-19 a lion inside of my body.

When she was first infected with SARS-CoV-2 in January 2021, just two days before she had an appointment to be vaccinated, the virus hit her nervous system hard. For 23 days, she was in intense pain. She felt like she was choking, that her throat and mouth were swelling, and that she couldnt breathe.

It was very painful, like I was being attacked and played with, like a small toy. That's how I describe the waves of pain and the movement of the virus around my body, says Street, who lives in Flagstaff with her son.

After the acute infection, Street still experienced debilitating symptoms for months. Now, about a year later, those symptoms ebb and flow, but she has still had to give up all the physical activities she once loved. She has chronic fatigue that flares up whenever she exerts herself, causing a tension at the base of her skull, brain fog and pain that reverberates through her body.

Its just going on for so long for me, and it's so impactful, and it's terrifying, at a time when the sleeping lion likes to wake up and scratch around, she said.

Viral facts

The phenomenon we currently know as long COVID highlights a vexing reality of many viral infections: Some people develop serious or chronic symptoms when most others do not.

A recently confirmed connection between Epstein-Barr virus, which infects many people, and multiple sclerosis, which afflicts only a few, is another example.

Proving that link lies in confirming a temporal connection in other words, showing definitively that the viral infection happened before the onset of the disease. That can take a generation to confirm.

Whether or not someone develops severe symptoms related to a viral infection also may depend on other factors such as the microbiome and genetics.

While research raises the prospect of better treating viral infections, researchers note a lack of access to basic health care may still be the greatest barrier.

Streets son, a teenager, was ill with COVID-19 too in fact, Street thinks she got the virus from him. He had some persistent symptoms as well, but they were completely different. He had bouts of swollen glands and rashes, but nothing like the fatigue that sidelined his mother from her work, hobbies and outdoor activities.

Why did her sons version of long COVID, as she calls it, look so different than her own? Street wants to know. I just think that's what science is going to catch up with ... How the body reacts differently, she said.

Its a question that has long intrigued scientists who study all kinds of viruses, particularly latent viruses the ones that infect nearly everyone, often when we are children, and then stick around in the body for the rest of our lives. Often they are asymptomatic, and we never even notice theyre there. But new research suggests that there might be more late-onset and damaging effects associated with latent viruses than some scientists initially thought.

In one pioneering study this January, researchers at Harvard found a causal link between Epstein-Barr virus (or EBV, which most people contract, and which gives a few unlucky individuals mononucleosis) and multiple sclerosis (MS). The study, which has been over 20 years in the making, has implications for what may one day be revealed about long COVID, said Elizabeth Jacobs, a professor of epidemiology and biostatistics at the University of Arizona whose team has already begun studying COVID-19 long haulers.

We're expecting decades, decades of research on this, she said.

Although the mechanisms of SARS-CoV-2 are different from those of true latent viruses the coronavirus might not stick around in the body as long as or in the same ways as, say, EBV scientists are looking at reactivation of latent viruses, and other existing post-infection syndromes, for answers about long-haul COVID-19. For long haulers, for sure, I can tell you that we're going to be looking at other viruses, said Dr. Janko Nikolich-ugich, the head of the immunobiology department at the University of Arizona and co-director of the Arizona Center on Aging.

Nikolich-ugich, who is also part of a team that recently received a $9.2 million grant to study long COVID, said that he and other researchers are interested in examining the relationship between long COVID and latent viruses because it is probably the interplay between the host and the viruses that will determine why one person got (long COVID) and the other person just sailed through, he said.

But uncovering temporal and causal connections between latent viruses and long COVID could take a while. Thats why scientists are looking to existing knowledge, like the recently-confirmed connection between EBV and MS, for a glimpse of the future.

Virus case file: SARS-CoV-2

Commonly known as: Novel coronavirus, COVID-19.

What it is: RNA virus in the coronavirus family.

How you catch it: Breathing in the respiratory droplets of an infected person. Researchers are still investigating the extent to which airborne and surface transmission also play a role.

What happens first: While some infections are completely asymptomatic, others cause a range of symptoms including fever, cough, loss of smell and taste, body aches, fatigue, brain fog, and in more severe cases, hospitalization and death.

The latent phase: SARS-CoV-2 is NOT a latent virus. However, some researchers have begun to suggest that viral reservoirs can persist in some people for several months after infection in various tissues throughout the body.

What happens later: Some patients experience months- or even years-long symptoms that have been collectively described under the umbrella of long COVID. These wide-ranging and highly individualized symptoms include conditions like severe fatigue or intolerance to physical activity, persistent brain fog, extended loss of or changes in smell and taste, chronic pain, cardiovascular or GI issues and more.

What else it might be causing: Too early to tell.

Treatment/vaccine status: Several effective vaccines are available, as well as a preventative monoclonal antibody cocktail for the immunocompromised. Treatments include new antivirals and monoclonal antibody infusions. Not all treatments/vaccines are as effective against the omicron variant as they are against other strains.

Just over 20 years ago, Kassandra Munger, now a senior research scientist at Harvard, was working on her Masters in epidemiology when she started getting interested in MS research. As a relative of someone with MS, she wanted to learn more about the causes and risk factors for the disease. By 2001, Munger and a colleague had published a paper in the Journal of the American Medical Association establishing a link between higher levels of EBV antibodies and increased risk of MS.

But they needed more evidence to prove there were temporal links between EBV and MS in other words, that EBV infection itself happens before the onset of MS.

So for two decades, Munger and her team collaborated with the U.S. military, using a cohort over several years that numbered over 10 million people. With a population that size, they were able to find what they really needed a group of people who, when they were first identified and tested, had not yet contracted EBV. Most of that group were younger than 20 years old at the time of their first blood samples.

The researchers found that 34 of 35 individuals who were EBV-negative at the beginning and developed MS during the study had contracted EBV about 5 to ten years before the onset of MS. All 766 other individuals in the cohort who developed MS were EBV-positive before the study, too, meaning that 800 out of 801 individuals total who developed MS were previously infected with EBV.

Munger said that its not clear exactly whats going on with the one EBV-negative case, but since MS is a collection of symptoms and there is no one laboratory test to diagnose the disease, its possible that person was misdiagnosed or that other factors were contributing to their symptoms.

The researchers also tested the association with over 200 other viruses, including over a dozen latent viruses, and found that EBV was the only virus for which those who developed MS had higher antibody levels than controls.

MS is a rare disease, and not everyone who gets EBV will get MS. But the temporal link shows that, in the vast majority of cases, EBV is necessary for MS.

Thats a tangible place to start looking for solutions, and one of those would be obvious: vaccination. If MS almost never occurs without first contracting EBV, a vaccine for the virus should help prevent the later disease. Moderna, which made one of the most effective COVID-19 vaccines, has already started testing an EBV vaccine in clinical trials.

But beyond vaccines, the findings are a solid starting point for understanding the relationship between viruses and long-term effects in our bodies later in life.

Whats more, when they looked at EBV in relation to other viruses, Munger and her team found another fascinating relationship. Among individuals who had EBV, those who had also been infected with cytomegalovirus (CMV) showed a decreased risk of developing MS. It was a finding consistent with existing research, but it still left them with more questions.

We have no idea what the biological mechanism would be. Maybe…there is some temporal relationship there, that maybe being infected with CMV first provides some sort of protection once you're infected with EBV, Munger said. So it's an interesting finding and clearly speaks to the complexity of this. It's easy in a headline to pull out, you know, EBV causes MS. But it's so much more complex than what that captures.

Virus case file: Epstein-Barr virus

Commonly known as: EBV, Infectious mononucleosis (mono), kissing disease."

What it is: DNA virus in the herpesvirus family.

How you catch it: Spread through bodily fluids, most commonly saliva.

What happens first: Often asymptomatic if infected in childhood; infections in teenage years or later in life sometimes feature characteristic mono symptoms such as swollen lymph nodes, fatigue, fever, sore or inflamed throat. Occasionally causes rashes, an enlarged spleen or swollen liver.

The latent phase: After initial infection, resides for life in throat and blood cells.

What happens later: Initial mono symptoms can sometimes last for several weeks or months before EBV becomes dormant. Reactivation sometimes causes symptoms in people with weakened immune systems.

What else it might be causing: A recent 20-year study proved that EBV infection is necessary for the development of multiple sclerosis (MS) later in life.

Treatment/vaccine status: Moderna began Phase I clinical trials for an EBV vaccine this January. While there are no widely available treatments for EBV, stem cell treatments have been used for some chronic cases in immunocompromised patients.

Sources: my.clevelandclinic.org; ncbi.nlm.nih.gov; cdc.gov; hopkinsmedicine.org; cdc.gov; sciencedirect.com; biospace.com; academic.oup.com.

That complexity the dazzling abundance of viruses, cells, proteins, bacteria and even fungi that work together, uniquely, within each individual person means that researchers have to be strategic and extremely specific with their experimental design. Knowing what questions to ask, and where to go next with the answers, is part of the challenge. There's an art, sometimes, to the interpretation, Munger said.

She also noted that over the last 20 years, as the research community has become more open to investigating the long-term effects of viruses like EBV, she and her team has had the chance to build on scientific criticisms and find more definitive answers. Its an iterative process that she says will need to be expanded now that SARS-CoV-2 has arrived on the scene. She thinks scientists will need to ask big Q questions, as she puts it, about the relationship between the novel coronavirus, other viruses, and long-term illnesses like MS.

But for now, she expressed appreciation for the definitive results they do have on MS,results that could still be a long time coming for COVID-19.

It really does feel like the culmination of 20 years of work, like we've climbed Mount Everest, Munger said. Maybe we haven't quite reached the peak. There's still a lot that we don't know. But certainly it has been an incremental build over the past 20 years to get to the point where we are now.

When Jacobs heard about the results from Mungers team, she had a message.

In looking at data from our prospective cohort study of COVID19, the Arizona CoVHORT, I have mentioned a few times that some of the symptoms of LongCOVID harmonize with the ones I have with MS, she tweeted on Jan.13, along with a link to Mungers paper in Science.

For Jacobs, better known to her over 13,000 Twitter followers as @TheAngryEpi, the paper was not only relevant to her research on COVID-19 but also to her own experience with MS. She was first diagnosed with MS in 2003, following her sisters diagnosis, and she says that ever since she has done everything she can to minimize her symptoms, which include fatigue, muscle aches and spasms, double vision and vertigo, as well as more severe issues that have sometimes left her unable to walk for weeks at a time.

While disease-modifying drugs and exercise have helped her keep the most severe degenerative effects of MS at bay, Jacobs said that she has seen her experience of certain symptoms reflected in the testimonials of long COVID patients. Jacobs is part of the public health research study called the Arizona CoVHORT, in which over two dozen University of Arizona researchers have surveyed thousands of people across the state to learn more about the effects of COVID-19.

She says that as of this summer, among participants whose symptoms were followed for more than two months, as many as 77% of participants were still reporting symptoms of long COVID at six months.

Jacobs said that while she didnt want to falsely equate long COVID and MS, she says the results she and her team are beginning to see amplified her concerns over the long-term effects of COVID-19 that still remain to be studied. What it did was break my heart, because I know those symptoms very well, and I was really hoping others would not be experiencing it, she said.

Its a concern that other scientists share. I would be surprised if there were no longer-term sequelae (consequential conditions) of COVID-19, but only time will tell at this point, Munger said.

In the meantime, Jacobs described her hope for long COVID advocates to keep sharing their experiences, because she has already witnessed a pattern of dismissal of MS symptoms from within and outside of the medical community.

Anecdotally, I know people with MS who went years without getting a diagnosis where people would brush them off … I am very familiar with that sense of not being believed, Jacobs said. It's real. It's happening … Don't just assume right away that this is in their head or something because that is what (has been) done to a lot of MS patients for decades.

Its a pattern that other advocacy groups have also highlighted. Patients with myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS), Lyme disease and other post-infection syndromes have taken to social media and other online forums to share their calls for further research and support from the medical establishment.

To that end, Jacobs said that the pandemic has brought together infectious disease and chronic disease epidemiologists, which has had an accelerating effect on collaborative efforts to better understand the long-term effects of SARS-CoV-2. Its a research area that is not only booming but also growing, changing and gaining more acceptance and more funding.

Before we were more siloed, she said. COVID in our case has made (interdisciplinary teamwork) more seamless than it was in the past.

Street doesnt know whats causing all of her symptoms. But she does worry about how long they have lasted, and what that could mean for her body in the future.

(Im anxious because) I'm not sure if the virus is sitting within me, Street said. Is it sitting in my system? Is it going to come back five years from now? That part could be terrifying if you sit and think about it too long.

Still, she added that she tries to stay positive and move on with her life as best she can. Shes working part-time now, some of her symptoms are getting better, and she has found some relief through acupuncture several times a week. Recently, after 13 months, says that an osteopath diagnosed her with costochondritis, or inflammation of the cartilage that connects the ribs to the breastbone. While she says that the diagnosis doesnt take the issue away, she is relieved to have more information.

She has also signed up to participate in the University of Arizona CoVHORT study as well as a study on long COVID sponsored by the National Institutes of Health (NIH), as she waits for more answers.

Those answers could be different for her than for others with long COVID, explained Amy Proal, a microbiologist at the PolyBio Research Foundation, in a webinar where she discussed potential biological factors contributing to long COVID, including latent virus reactivation and dysregulation of the microbiome. According to Proal, the condition may very well represent a continuum of different effects within the body.

In one person, for example, a reservoir of SARS-CoV-2 may lurk in the intestinal tissue, sending inflammatory signals to the brain and resulting in sickness, nausea or other nervous system symptoms. While scientists still arent sure exactly how long the virus might persist in the body, a recent preprint from a team at the National Institutes of Health and other institutions suggests, based on autopsy data, that SARS-CoV-2 RNA might persist in the bodies of some patients for months.

But in another person, the coronavirus could have been cleared from the body, and yet it may have also caused a reactivation of Epstein-Barr virus in the process and disrupted the microbiome eventually resulting in those same or similar sickness, nausea and nervous system symptoms.

A takeaway is that if the same circuitry is being impacted, no two long COVID patients have to have the exact same mix of pathogens or inflammatory issues to develop these same sets of common symptoms, Proal said.

Its an idea that has been relevant to several other conditions in the past, but is only now being thrust into the limelight, said Michael VanElzakker, a neuroscience researcher at Massachusetts General Hospital and Harvard Medical School who worked with Proal to outline a list of biological factors that could lead to long COVID.

VanElzakker previously specialized in studying the long-term consequences of acute infections years and years, as he puts it, of trying to convey that some people don't fully recover from apparently infectious illness…and just trying to get it taken seriously.

He described how many poorly understood autoimmune conditions may really be a consequence of the immune system trying to get at something that was doing damage. He echoed the connections some advocates and researchers have drawn between long COVID and other conditions like Lyme disease, MS, and chronic fatigue syndrome, noting parallels in the ways some physicians have dismissed the so-called vague symptoms patients with those diseases often report.

VanElzakker added that many of those symptoms are actually clear markers of the immune response, and that breaking down the artificial barriers scientists have drawn between the nervous system and the immune system could lead to breakthroughs that address the root causes of many diseases root causes that might look different from person to person.

Its probably … going to take, you know, some thoughtful, genuinely personalized medicine to figure out what's happening in each person, he said.

Its a topic Jacobs has been bringing up in her classes as she asks students to wrestle with questions of justice and healthcare. Personalized medicine is like the bells and whistles, super space-age-like medicine … but it does ignore what to me is the biggest problem in health care right now, which is lack of access, she said. Poverty, for example, is a carcinogen. … I actually believe that (improving access) would be more effective in the next decade than personalized medicine.

VanElzakker observes similar disparities related to his own work, which he thinks will have implications for the kinds of care and support different patients will be able to receive in the future. This is one of the things that's both really invigorating and frustrating about research, he said. We're working on some amazing ways to test tissues. … But the idea that (someone without health insurance or adequate resources) that has long COVID is going to have access to that kind of stuff? Not for a while, not unless there's a big change.

While they wait for that change, long COVID patients like Street have taken to social media and to grassroots movements like Survivor Corps, an online network, to find community. Street still says she has felt isolated at times, because no two experiences with long COVID are the same. That parts quite lonely, she said.

But with those unique symptoms come opportunities for better research and care, and VanElzakker is hopeful that the flood of data and innovation that COVID-19 has initiated will make waves in a field that he has been part of for a long time.

It is a really promising moment, VanElzakker said. Because SARS-CoV-2 is new, there's a space for discovery.

Melina Walling is a bioscience reporter who covers COVID-19, health, technology, agriculture and the environment. You can contact her via email at mwalling@gannett.com, or on Twitter @MelinaWalling.

Independent coverage of bioscience in Arizona is supported by a grant from the Flinn Foundation.

Link:
Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic

In many areas of bioprocessing, cell adhesion and detachment pose fundamental challenges. Personalized medicine and other novel biomedical applications require the cultivation and handling of cells that mainly adhere on surfaces, says Katja Uhlig, PhD, a group leader at the Fraunhofer Institute for Cell Therapy and Immunology in Potsdam, Germany. So, cell attachment plays a crucial role in successful cell expansion. The cells must also be easily detached from the culturing surface.

Nonetheless, the kind of cells being cultured dictates the best surface for adhesion and detachment. This diversity poses a challenge to technical solutions for new surfaces that promise broad applicability for various cell types, says Uhlig.

Katja Uhlig, PhD. [Katja Uhlig (iklick photo studio)]Thermoresponsive polymers offer a promising coating. With thermoresponsive polymer coatings, cultured cells can be detached from a substrate within 30 minutes just by changing the temperature from 37C to room temperature. Plus, thermoresponsive polymer coatings provide two main advantages over conventional enzymatic digestion.

First, the membrane proteins are not digested, so the treatment is gentler on the cells, Uhlig explains. Second, there are fewer process steps since rinsing and inhibition of the enzymes are omitted. These advantages could improve the efficiency of cell cultivation on a larger scale, such as in bioreactors.

Although thermoresponsive polymer coatings are not new in cell culture, Uhlig points out that the coating procedures have been too complicated and costly to replace standard methods. To address those concerns, Uhlig and her colleagues spray the thermoresponsive polymer on conventional cell-culture materials. That makes the process inexpensive and flexible to use, she says.

To put this method into commercial bioprocessing, the synthesis of thermoresponsive polymer coatings must be scaled up and the spray-coating process must be automated. Still, Uhlig says: We hope that our contribution will modernize cell culture and make the process easier and gentler for the cells.

Read more:
Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News